import { jsx as _jsx, jsxs as _jsxs, Fragment as _Fragment } from "react/jsx-runtime";
import CitationCard from "@/app/components/citation-card/citation-card.tsx";
import { MyNode } from "@/models/node";
import { NIAAA } from "@/public/citations";
const PET = new MyNode("PET", [], (_jsxs("div", { children: [_jsx(CitationCard, { citations: [NIAAA], children: "Tau PET: This emerging imaging modality targets PHF tau deposits in the brain but faces limitations, such as off-target binding. The first-generation ligand, flortaucipir, is a reliable marker for 3R/4R PHF tau, correlating with Braak staging and cognitive impairment. Newer ligands are in development to improve specificity and reduce off-target effects. Tau PET and CSF P-tau cannot detect minimal neurofibrillary changes, impacting the diagnostic distinction between \u201CAlzheimer\u2019s pathologic change\u201D and full AD." }), _jsx(CitationCard, { citations: [NIAAA], children: "Amyloid PET: Sensitivity thresholds are set by typical cut points for PET ligands. For example: 18F Amyloid PET: Labels moderate to high neuritic plaque loads as abnormal but may miss low plaque levels. 11C Pittsburgh Compound B: Categorizes individuals with Thal phase 2\u20135 as abnormal, potentially missing early plaque stages (Thal 0\u20131). Consequently, a negative amyloid PET does not necessarily indicate a complete absence of amyloid-beta (A\u03B2) or neuritic plaques, as subtle pathologic changes can still occur below detection thresholds, sometimes causing mild cognitive effects." })] })));
export const Wrapper = () => _jsx(_Fragment, { children: PET.content });
export default PET;
